Login to Your Account



Other News To Note


Thursday, August 4, 2011
NPS Pharmaceuticals Inc., of Bedminster, N.J., partnered with GlaxoSmithKline plc, of London, to develop two calcilytic compounds currently belonging to GSK. The compounds have relevance for rare disorders of calcium receptor activity, including hypocalcemia with hypercalciuria.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription